PM01183 Iniciara la Fase II : " Alone or in Combination with Gemcitabine in Comparison to Docetaxel for the Treatment of Unresectable Non-Small Cell Lung Cancer ( NSCLC ) Patients " en EEUU el mes que viene en el Montefiore Medical Center de New York .

Recruitment Information :

Status Not yet recruiting
Start date 2013-11
Last follow-up date 2015-12 (Anticipated)
Primary completion date 2015-12 (Anticipated)


Administrative Data :

Organization name PharmaMar
Organization study ID PM1183-B-004-13
Sponsor PharmaMar
Health Authority United States: Food and Drug Administration

...